查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1944390

全球藥物定序市場：按部署方法、治療領域、最終用途、藥物分子、方法類型、給藥途徑、國家和地區分類－產業分析、市場規模、佔有率和預測（2025-2032）

Drug Repurposing Market, By Deployment Mode, By Therapeutic Area, By End Use, By Drug Molecules, By Type of Approach, By Route of Administration, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 349 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2024 年，現有藥物定序市場價值將達到 330.181 億美元，從 2025 年到 2032 年的複合年成長率將達到 4.30%。

藥物定序市場專注於識別和開發現有或已獲核准藥物的新治療用途，與傳統藥物研發方法相比，能夠更快、更經濟高效地開發治療方法。研發成本的不斷攀升以及加速複雜罕見疾病治療方法的迫切需求是推動市場成長的主要因素。人工智慧 (AI) 和真實世界數據在發現新型藥物-疾病關聯的應用日益廣泛，是該市場的關鍵趨勢。然而，監管的不確定性、智慧財產權限制以及資料檢驗方面的挑戰都構成了重大障礙。儘管存在這些障礙，但對罕見疾病、腫瘤和新興感染疾病的日益關注為藥物定序提供了巨大的機遇，它可以縮短研發週期、降低失敗風險並最大限度地發揮現有藥物資產的臨床價值。

藥物定序的市場動態

醫療保健成本上升推動藥物定序市場成長

全球醫療保健支出不斷成長是推動藥物定序市場發展的主要動力。醫療保健支出涵蓋預防、診斷、治療、復健和醫療保健管理等各個方面，由於醫療成本上升、技術進步以及對醫療服務需求的不斷成長，醫療保健支出持續攀升。不斷成長的醫療支出促使人們增加對研究活動、臨床試驗和數據驅動型研究的投資，而這些對於發現現有藥物的新治療適應症至關重要。這一趨勢極大地促進了藥物定序，因為它提供了一種比傳統藥物研發成本更低、速度更快的替代方案。根據美國醫療保險和醫療補助服務中心於2022年3月發布的《2021-2030年國家醫療保健支出報告》，預計到2030年，美國國家醫療保健支出將以每年平均5.1%的速度成長，達到約6.8兆美元。不斷成長的醫療保險和醫療補助支出將有助於為藥物再利用研究提供資金，從而加速市場擴張。

藥物定序市場：細分分析

全球藥物定序市場按引入方式、治療領域、最終用途、藥物分子、方法類型、給藥途徑和地區進行細分。

腫瘤治療佔據了相當大的市場佔有率，這主要得益於全球癌症高發病率以及對更有效、更易獲得的治療方案的巨大未滿足需求。現有的癌症藥物或最初核准用於非腫瘤適應症的治療方法，正擴大被評估用於新的癌症治療，其依據是已確立的安全性和有效性，從而縮短了研發週期。這項策略顯著降低了新癌症療法的研發成本和所需時間。例如，2024年12月，德州大學西南醫學中心的研究人員報告稱，一種獲得FDA核准用於治療多發性骨髓瘤和淋巴瘤的藥物，在KRAS突變型非小細胞肺癌患者中顯示出腫瘤消退的現象。同時，諸如ReDO計劃等措施正在推動非腫瘤藥物的再利用，用於腫瘤治療，重點在於提供有效且低毒性的治療方案。

按最終用途分類，製藥和生物技術公司佔據了大部分收入佔有率。這些公司擁有完善的基礎設施、強大的研發能力和豐富的監管經驗，使其能夠有效地將現有藥物用於新的適應症。它們雄厚的財力有助於資金籌措臨床試驗和收購有前景的候選藥物。此外，日益成長的醫療保健缺口需求和對低成本治療方法的需求也促使這些公司考慮藥物再利用策略。 2022年5月，美國食品藥物管理局（FDA）核准Baricitinib用於治療需要不同程度呼吸支持的COVID-19住院成人患者。此前， 核准於2020年11月發布了緊急使用授權（EUA），授權Baricitinib替尼聯合治療瑞德西韋用於治療COVID-19住院成人和兒童患者。此次核准基於適應性COVID-19治療試驗（ACTT-2）的結果，該試驗表明，聯合治療縮短了住院患者的康復時間並改善了臨床療效。

藥物定序市場—區域分析

北美市場主導。這一成長得益於先進的研究基礎設施、有利的監管環境以及對老藥新用藥物的快速核准。此外，該地區還促進了人工智慧Start-Ups、研究中心和大型製藥企業之間的緊密合作，共同開發針對各種疾病的老藥新用藥物。 2025年8月，Fifty 1 Labs, Inc.的子公司Fifty 1 AI Labs與LUNR Aerospace合作，共同開發一項用於太空醫學的人工智慧驅動型藥物定序舉措。

美國藥物定序市場—國家分析

美國是北美的重要市場，其蓬勃發展的製藥和生技產業正推動著對人工智慧驅動的藥物研發平台的投資。例如，總部位於麻薩諸塞州的Lyra Sciences公司於2025年9月完成了2.35億美元的A輪資金籌措，用於擴展其人工智慧驅動的自主實驗室。這筆資金將用於擴建Lyra位於波士頓、舊金山和倫敦的「人工智慧科學工廠」。在這些工廠中，人工智慧模型能夠提出假設、運行實驗、從結果中學習，並不斷迭代，直到整個流程完成。美國良好的資金籌措環境，以及學術機構與人工智慧解決方案供應商之間成熟的合作關係，持續推動大規模的再利用計畫。

目錄

第1章：藥物定序市場概覽

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：藥物定序的主要市場趨勢

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 未來市場趨勢

4. 藥物定序市場：產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長展望：概覽
  • 管理體制分析

第5章 藥物定序市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：藥物定序市場現狀

  • 藥物定序市佔率分析（2024 年）
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章 依部署方式分類的藥物定序市場

  • 概述
    • 按部署模式分類的細分市場佔有率分析
    • 本地部署
    • 基於雲端的

8. 按治療領域分類的藥物定序市場

  • 概述
    • 細分市場佔有率分析：依治療領域分類
    • 腫瘤學
    • 循環系統疾病
    • 感染疾病
    • 罕見疾病
    • 神經病學
    • 免疫學
    • 代謝性疾病
    • 其他

9. 按最終用途分類的藥物定序市場

  • 概述
    • 細分市場佔有率分析：依最終用途分類
    • CRO（委外研發機構）
    • 製藥和生物技術公司
    • 醫療保健提供者
    • 學術和研究機構
    • 其他

10. 依藥物分子分類的藥物定序市場

  • 概述
    • 細分市場佔有率分析：依藥物分子分類
    • 胜肽
    • 生物製藥
    • 疫苗
    • 常規小分子化合物
    • 其他

第11章：依方法類型分類的藥物定序市場

  • 概述
    • 細分市場佔有率分析：依方法類型
    • 以目標為中心
    • 以疾病為中心
    • 以藥物為中心

第12章：按給藥途徑分類的藥物定序市場

  • 概述
    • 細分市場佔有率分析：依管理途徑
    • 靜脈注射
    • 口服
    • 其他給藥途徑

第13章 各地區的藥物定序市場

  • 介紹
  • 北美洲
    • 概述
    • 北美主要製造商
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲主要製造商
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 其他
  • 亞太地區
    • 概述
    • 亞太地區主要製造商
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 其他
  • 拉丁美洲
    • 概述
    • 拉丁美洲主要製造商
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他
  • 中東和非洲
    • 概述
    • 中東和非洲的主要製造商
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 其他

第14章 主要供應商分析－藥物定序產業

  • 競爭對手儀錶板
    • 競爭基準
    • 競爭定位
  • 公司簡介
    • Eli Lilly and Company
    • GSK plc
    • Amgen Inc.
    • Biogen Inc.
    • Pfizer Inc.
    • Roche Holding AG
    • Novartis AG
    • AbbVie
    • Amgen
    • Boehringer Ingelheim
    • Cyclica
    • GlaxoSmithKline
    • Vertex Pharmaceuticals
    • Melior Discovery
    • Pharnext
    • Recursion Pharmaceuticals
    • Revolution Medicines
    • Sanofi
    • Schwarz Pharma
    • Valence Discovery
    • Bayer AG
    • Teva Pharmaceutical
    • Others

第15章 AnalystView 360度分析

簡介目錄
Product Code: ANV5994

Drug Repurposing Market size was valued at US$ 33,018.10 Million in 2024, expanding at a CAGR of 4.30% from 2025 to 2032.

The drug repurposing market focuses on identifying and developing new therapeutic uses for existing or previously approved drugs, allowing for faster and more cost-effective treatment development than traditional drug discovery. Rising R&D costs and the urgent need to accelerate therapies for complex and rare diseases are the primary drivers of market growth. The increasing use of artificial intelligence and real-world data to discover novel drug-disease relationships is a major market trend. However, regulatory uncertainties, intellectual property limitations, and data validation challenges all act as significant barriers. Despite these obstacles, a greater emphasis on rare diseases, oncology, and emerging infectious conditions presents significant opportunities for drug repurposing, which reduces development timelines, lowers failure risk, and maximizes the clinical value of existing pharmaceutical assets.

Drug Repurposing Market- Market Dynamics

Rising Healthcare Expenditure Driving Drug Repurposing Market Growth

The increasing level of global healthcare expenditure is a major driver of the drug repurposing market's growth. Healthcare spending includes prevention, diagnosis, treatment, rehabilitation, and healthcare administration, and it is increasing due to rising medical costs, technological advancements, and increased demand for healthcare services. Increased healthcare spending allows for more investment in research activities, clinical trials, and data-driven studies, all of which are critical for discovering new therapeutic indications for existing drugs. This trend benefits drug repurposing significantly because it provides a less expensive and faster alternative to traditional drug discovery. According to the 2021-2030 National Health Expenditure report published by the United States Centers for Medicare & Medicaid Services in March 2022, national health spending is expected to increase at an average annual rate of 5.1%, reaching nearly USD 6.8 trillion by 2030. Rising Medicare and Medicaid spending boosts funding availability for repurposing research, hastening market expansion.

Drug Repurposing Market- Segmentation Analysis:

The Global Drug Repurposing Market is segmented on the basis of Deployment Mode, Therapeutic Area, End Use, Drug Molecules, Type of Approach, Route of Administration, and Region.

Oncology represents a significant share of the market, driven by the high global prevalence of cancer and the substantial unmet need for more effective and accessible treatment options. A growing number of existing oncology drugs, as well as therapies originally approved for non-oncologic indications, are being evaluated for new cancer applications by leveraging their established safety and efficacy profiles to accelerate development timelines. This strategy significantly reduces both the cost and time required to introduce new cancer treatments. For example, in December 2024, researchers at UT Southwestern reported that an FDA-approved therapy for multiple myeloma and lymphoma demonstrated tumor-shrinking effects in patients with KRAS-mutated non-small cell lung cancer. In parallel, initiatives such as the ReDO Project are advancing the repurposing of non-cancer drugs for oncology, with a focus on delivering effective, low-toxicity treatment alternatives.

Based on End Use, Pharmaceutical and biotechnology companies account for the majority of revenue share. These companies have established infrastructure, extensive R&D capabilities, and regulatory expertise, allowing them to effectively repurpose existing drugs for new indications. Their vast financial resources make it easier to fund clinical trials and acquire promising drug candidates. Furthermore, the growing need to fill gaps in medical care and the demand for low-cost therapies have prompted these companies to investigate repurposing strategies. The United States Food and Drug Administration (FDA) approved baricitinib in May 2022 for the treatment of hospitalized adults who require varying degrees of respiratory support as a result of COVID-19. This approval followed an earlier Emergency Use Authorization (EUA) issued in November 2020 for the combination of baricitinib and remdesivir in the treatment of COVID-19 in hospitalized adults and pediatric patients. The approval was based on results from the Adaptive COVID-19 Treatment Trial (ACTT-2), which showed that the combination therapy shortened recovery time and improved clinical outcomes in hospitalized patients..

Drug Repurposing Market- Geographical Insights

North America dominates the market. The expansion is fueled by advanced research infrastructure, supportive regulatory landscapes, and faster approval for repurposed drugs. In addition, this region is promoting strong collaborations between AI startups, research centers, and large pharmaceutical companies to develop repurposed drugs for various diseases. In August 2025, Fifty 1 AI Labs, a subsidiary of Fifty 1 Labs, Inc., collaborated with LUNR Aerospace to develop AI-powered drug repurposing initiatives for space medicine.

United States Drug Repurposing Market- Country Insights

The United States is the major North American market, driven by a thriving pharmaceutical and biotechnology industry that is investing in AI-powered drug discovery platforms. For example, in September 2025, Massachusetts-based Lila Sciences raised USD 235 million in a Series A round to expand its AI-powered autonomous laboratories. The funds are raised to expand Lila's "AI Science Factories" in Boston, San Francisco, and London, where AI models develop hypotheses, run experiments, learn from results, and iterate from start to finish. The nation's strong financing environment, combined with mature collaborations between academia and AI solution providers, continues to drive large-scale repurposing programs.

Drug Repurposing Market- Competitive Landscape:

The drug repurposing market is distinguished by collaborations among pharmaceutical companies, biotech firms, research institutions, and technology providers aimed at discovering new therapeutic applications for existing medications. Strategic partnerships, licensing agreements, and investments in advanced computational platforms that accelerate drug repurposing research all have an impact on competition. Companies are increasingly relying on artificial intelligence, real-world evidence, and big data analytics to improve target identification, streamline clinical validation, and lower development costs. Regulatory alignment and shared research frameworks also have an impact on competitive positioning. Novartis AG, Pfizer Inc., Eli Lilly and Company, and Bayer AG are key players driving innovation and commercial activity in the drug repurposing market. These organizations use extensive compound libraries, global R&D capabilities, and strategic alliances to broaden their repurposed drug portfolios and increase market visibility.

In April 2025, Novartis agreed to acquire Regulus Therapeutics, a San Diego-based clinical-stage biopharmaceutical company focused on microRNA therapies. Faburden, Regulus' leading asset, targets miR-17 and has the potential to be a first-in-class treatment for autosomal dominant polycystic kidney disease (ADPKD). This acquisition complements Novartis' focus on renal disease and will increase its expertise in this therapeutic area. The acquisition expands Novartis' portfolio by incorporating novel approaches to treating kidney diseases.

Recent Developments:

In April 2025, Qualthera Health Corporation, which is dedicated to establishing a nationwide network of quality, patient-centered compounding pharmacies, has announced the official launch of Qualthera Pharmaceuticals Ltd. Co., a research-driven subsidiary focused on drug repurposing and innovative delivery systems. This expansion is a significant step forward in accelerating pharmaceutical innovation by leveraging real-world patient insights to create new therapies with streamlined development.

In June 2024, BioXcel Therapeutics used artificial intelligence-based drug repurposing to discover new applications for drug candidates that had stalled in development. The company accelerates therapeutic innovation by integrating approved and established drugs, clinically validated candidates, big data, and proprietary machine learning algorithms. It is focused on research and development costs, market access, and growth in neurology and immuno-oncology within the drug repurposing market.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DRUG REPURPOSING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Eli Lilly and Company
  • GSK plc
  • Amgen Inc.
  • Biogen Inc.
  • Pfizer Inc.
  • Roche Holding AG
  • Novartis AG
  • AbbVie
  • Amgen
  • Boehringer Ingelheim
  • Cyclica
  • GlaxoSmithKline
  • Vertex Pharmaceuticals
  • Melior Discovery
  • Pharnext
  • Recursion Pharmaceuticals
  • Revolution Medicines
  • Sanofi
  • Schwarz Pharma
  • Valence Discovery
  • Bayer AG
  • Teva Pharmaceutical
  • Others

GLOBAL DRUG REPURPOSING MARKET, BY DEPLOYMENT MODE- MARKET ANALYSIS, 2019 - 2032

  • On-premises
  • Cloud-based

GLOBAL DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

  • Oncology
  • Cardiovascular Diseases
  • Infectious Diseases
  • Rare Diseases
  • Neurology
  • Immunology
  • Metabolic Disorders
  • Others

GLOBAL DRUG REPURPOSING MARKET, BY END USE- MARKET ANALYSIS, 2019 - 2032

  • Contract Research Organizations (CROs)
  • Pharmaceutical & Biotechnology Companies
  • Healthcare Providers
  • Academic & Research Institutes
  • Others

GLOBAL DRUG REPURPOSING MARKET, BY DRUG MOLECULES- MARKET ANALYSIS, 2019 - 2032

  • Peptides
  • Biologics
  • Vaccines
  • Conventional Small Molecules
  • Others

GLOBAL DRUG REPURPOSING MARKET, BY TYPE OF APPROACH- MARKET ANALYSIS, 2019 - 2032

  • Target-centric
  • Disease-centric
  • Drug-centric

GLOBAL DRUG REPURPOSING MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Intravenous
  • Oral
  • Other routes of administration

GLOBAL DRUG REPURPOSING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Drug Repurposing Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Drug Repurposing Market Snippet by Deployment Mode
    • 2.1.2. Drug Repurposing Market Snippet by Therapeutic Area
    • 2.1.3. Drug Repurposing Market Snippet by End Use
    • 2.1.4. Drug Repurposing Market Snippet by Drug Molecules
    • 2.1.5. Drug Repurposing Market Snippet by Type of Approach
    • 2.1.6. Drug Repurposing Market Snippet by Route of Administration
    • 2.1.7. Drug Repurposing Market Snippet by Country
    • 2.1.8. Drug Repurposing Market Snippet by Region
  • 2.2. Competitive Insights

3. Drug Repurposing Key Market Trends

  • 3.1. Drug Repurposing Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Drug Repurposing Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Drug Repurposing Market Opportunities
  • 3.4. Drug Repurposing Market Future Trends

4. Drug Repurposing Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Drug Repurposing Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Drug Repurposing Market Landscape

  • 6.1. Drug Repurposing Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Drug Repurposing Market - By Deployment Mode

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Deployment Mode, 2024 & 2032 (%)
    • 7.1.2. On-premises
    • 7.1.3. Cloud-based

8. Drug Repurposing Market - By Therapeutic Area

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Therapeutic Area, 2024 & 2032 (%)
    • 8.1.2. Oncology
    • 8.1.3. Cardiovascular Diseases
    • 8.1.4. Infectious Diseases
    • 8.1.5. Rare Diseases
    • 8.1.6. Neurology
    • 8.1.7. Immunology
    • 8.1.8. Metabolic Disorders
    • 8.1.9. Others

9. Drug Repurposing Market - By End Use

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End Use, 2024 & 2032 (%)
    • 9.1.2. Contract Research Organizations (CROs)
    • 9.1.3. Pharmaceutical & Biotechnology Companies
    • 9.1.4. Healthcare Providers
    • 9.1.5. Academic & Research Institutes
    • 9.1.6. Others

10. Drug Repurposing Market - By Drug Molecules

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Drug Molecules, 2024 & 2032 (%)
    • 10.1.2. Peptides
    • 10.1.3. Biologics
    • 10.1.4. Vaccines
    • 10.1.5. Conventional Small Molecules
    • 10.1.6. Others

11. Drug Repurposing Market - By Type of Approach

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Type of Approach, 2024 & 2032 (%)
    • 11.1.2. Target-centric
    • 11.1.3. Disease-centric
    • 11.1.4. Drug-centric

12. Drug Repurposing Market - By Route of Administration

  • 12.1. Overview
    • 12.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 12.1.2. Intravenous
    • 12.1.3. Oral
    • 12.1.4. Other routes of administration

13. Drug Repurposing Market- By Geography

  • 13.1. Introduction
    • 13.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 13.2. North America
    • 13.2.1. Overview
    • 13.2.2. Drug Repurposing Key Manufacturers in North America
    • 13.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 13.2.4. North America Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
    • 13.2.5. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 13.2.6. North America Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 13.2.7. North America Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
    • 13.2.8. North America Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
    • 13.2.9. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.2.10. U.S.
      • 13.2.10.1. Overview
      • 13.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.2.10.3. U.S. Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.2.10.4. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.2.10.5. U.S. Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.2.10.6. U.S. Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.2.10.7. U.S. Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.2.10.8. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.2.11. Canada
      • 13.2.11.1. Overview
      • 13.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.2.11.3. Canada Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.2.11.4. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.2.11.5. Canada Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.2.11.6. Canada Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.2.11.7. Canada Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.2.11.8. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 13.3. Europe
    • 13.3.1. Overview
    • 13.3.2. Drug Repurposing Key Manufacturers in Europe
    • 13.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 13.3.4. Europe Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
    • 13.3.5. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 13.3.6. Europe Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 13.3.7. Europe Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
    • 13.3.8. Europe Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
    • 13.3.9. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.3.10. Germany
      • 13.3.10.1. Overview
      • 13.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.10.3. Germany Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.3.10.4. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.3.10.5. Germany Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.3.10.6. Germany Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.3.10.7. Germany Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.3.10.8. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.3.11. UK
      • 13.3.11.1. Overview
      • 13.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.11.3. UK Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.3.11.4. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.3.11.5. UK Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.3.11.6. UK Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.3.11.7. UK Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.3.11.8. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.3.12. France
      • 13.3.12.1. Overview
      • 13.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.12.3. France Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.3.12.4. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.3.12.5. France Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.3.12.6. France Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.3.12.7. France Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.3.12.8. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.3.13. Italy
      • 13.3.13.1. Overview
      • 13.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.13.3. Italy Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.3.13.4. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.3.13.5. Italy Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.3.13.6. Italy Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.3.13.7. Italy Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.3.13.8. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.3.14. Spain
      • 13.3.14.1. Overview
      • 13.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.14.3. Spain Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.3.14.4. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.3.14.5. Spain Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.3.14.6. Spain Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.3.14.7. Spain Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.3.14.8. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.3.15. The Netherlands
      • 13.3.15.1. Overview
      • 13.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.15.3. The Netherlands Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.3.15.4. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.3.15.5. The Netherlands Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.3.15.6. The Netherlands Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.3.15.7. The Netherlands Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.3.15.8. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.3.16. Sweden
      • 13.3.16.1. Overview
      • 13.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.16.3. Sweden Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.3.16.4. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.3.16.5. Sweden Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.3.16.6. Sweden Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.3.16.7. Sweden Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.3.16.8. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.3.17. Russia
      • 13.3.17.1. Overview
      • 13.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.17.3. Russia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.3.17.4. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.3.17.5. Russia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.3.17.6. Russia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.3.17.7. Russia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.3.17.8. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.3.18. Poland
      • 13.3.18.1. Overview
      • 13.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.18.3. Poland Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.3.18.4. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.3.18.5. Poland Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.3.18.6. Poland Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.3.18.7. Poland Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.3.18.8. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.3.19. Rest of Europe
      • 13.3.19.1. Overview
      • 13.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.19.3. Rest of the Europe Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.3.19.4. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.3.19.5. Rest of the Europe Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.3.19.6. Rest of the Europe Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.3.19.7. Rest of the Europe Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.3.19.8. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 13.4. Asia Pacific (APAC)
    • 13.4.1. Overview
    • 13.4.2. Drug Repurposing Key Manufacturers in Asia Pacific
    • 13.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 13.4.4. APAC Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
    • 13.4.5. APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 13.4.6. APAC Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 13.4.7. APAC Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
    • 13.4.8. APAC Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
    • 13.4.9. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.4.10. China
      • 13.4.10.1. Overview
      • 13.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.10.3. China Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.4.10.4. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.4.10.5. China Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.4.10.6. China Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.4.10.7. China Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.4.10.8. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.4.11. India
      • 13.4.11.1. Overview
      • 13.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.11.3. India Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.4.11.4. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.4.11.5. India Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.4.11.6. India Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.4.11.7. India Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.4.11.8. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.4.12. Japan
      • 13.4.12.1. Overview
      • 13.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.12.3. Japan Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.4.12.4. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.4.12.5. Japan Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.4.12.6. Japan Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.4.12.7. Japan Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.4.12.8. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.4.13. South Korea
      • 13.4.13.1. Overview
      • 13.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.13.3. South Korea Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.4.13.4. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.4.13.5. South Korea Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.4.13.6. South Korea Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.4.13.7. South Korea Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.4.13.8. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.4.14. Australia
      • 13.4.14.1. Overview
      • 13.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.14.3. Australia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.4.14.4. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.4.14.5. Australia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.4.14.6. Australia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.4.14.7. Australia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.4.14.8. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.4.15. Indonesia
      • 13.4.15.1. Overview
      • 13.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.15.3. Indonesia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.4.15.4. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.4.15.5. Indonesia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.4.15.6. Indonesia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.4.15.7. Indonesia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.4.15.8. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.4.16. Thailand
      • 13.4.16.1. Overview
      • 13.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.16.3. Thailand Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.4.16.4. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.4.16.5. Thailand Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.4.16.6. Thailand Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.4.16.7. Thailand Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.4.16.8. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.4.17. Philippines
      • 13.4.17.1. Overview
      • 13.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.17.3. Philippines Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.4.17.4. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.4.17.5. Philippines Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.4.17.6. Philippines Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.4.17.7. Philippines Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.4.17.8. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.4.18. Rest of APAC
      • 13.4.18.1. Overview
      • 13.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.18.3. Rest of APAC Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.4.18.4. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.4.18.5. Rest of APAC Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.4.18.6. Rest of APAC Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.4.18.7. Rest of APAC Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.4.18.8. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 13.5. Latin America (LATAM)
    • 13.5.1. Overview
    • 13.5.2. Drug Repurposing Key Manufacturers in Latin America
    • 13.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 13.5.4. LATAM Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
    • 13.5.5. LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 13.5.6. LATAM Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 13.5.7. LATAM Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
    • 13.5.8. LATAM Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
    • 13.5.9. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.5.10. Brazil
      • 13.5.10.1. Overview
      • 13.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.5.10.3. Brazil Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.5.10.4. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.5.10.5. Brazil Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.5.10.6. Brazil Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.5.10.7. Brazil Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.5.10.8. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.5.11. Mexico
      • 13.5.11.1. Overview
      • 13.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.5.11.3. Mexico Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.5.11.4. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.5.11.5. Mexico Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.5.11.6. Mexico Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.5.11.7. Mexico Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.5.11.8. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.5.12. Argentina
      • 13.5.12.1. Overview
      • 13.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.5.12.3. Argentina Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.5.12.4. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.5.12.5. Argentina Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.5.12.6. Argentina Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.5.12.7. Argentina Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.5.12.8. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.5.13. Colombia
      • 13.5.13.1. Overview
      • 13.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.5.13.3. Colombia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.5.13.4. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.5.13.5. Colombia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.5.13.6. Colombia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.5.13.7. Colombia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.5.13.8. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.5.14. Rest of LATAM
      • 13.5.14.1. Overview
      • 13.5.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.5.14.3. Rest of LATAM Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.5.14.4. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.5.14.5. Rest of LATAM Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.5.14.6. Rest of LATAM Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.5.14.7. Rest of LATAM Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.5.14.8. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 13.6. Middle East and Africa
    • 13.6.1. Overview
    • 13.6.2. Drug Repurposing Key Manufacturers in Middle East and Africa
    • 13.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 13.6.4. Middle East and Africa Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
    • 13.6.5. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 13.6.6. Middle East and Africa Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 13.6.7. Middle East and Africa Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
    • 13.6.8. Middle East and Africa Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
    • 13.6.9. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.6.10. Saudi Arabia
      • 13.6.10.1. Overview
      • 13.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.10.3. Saudi Arabia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.6.10.4. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.6.10.5. Saudi Arabia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.6.10.6. Saudi Arabia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.6.10.7. Saudi Arabia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.6.10.8. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.6.11. United Arab Emirates
      • 13.6.11.1. Overview
      • 13.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.11.3. United Arab Emirates Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.6.11.4. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.6.11.5. United Arab Emirates Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.6.11.6. United Arab Emirates Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.6.11.7. United Arab Emirates Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.6.11.8. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.6.12. Israel
      • 13.6.12.1. Overview
      • 13.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.12.3. Israel Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.6.12.4. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.6.12.5. Israel Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.6.12.6. Israel Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.6.12.7. Israel Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.6.12.8. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.6.13. Turkey
      • 13.6.13.1. Overview
      • 13.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.13.3. Turkey Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.6.13.4. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.6.13.5. Turkey Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.6.13.6. Turkey Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.6.13.7. Turkey Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.6.13.8. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.6.14. Algeria
      • 13.6.14.1. Overview
      • 13.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.14.3. Algeria Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.6.14.4. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.6.14.5. Algeria Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.6.14.6. Algeria Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.6.14.7. Algeria Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.6.14.8. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.6.15. Egypt
      • 13.6.15.1. Overview
      • 13.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.15.3. Egypt Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.6.15.4. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.6.15.5. Egypt Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.6.15.6. Egypt Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.6.15.7. Egypt Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.6.15.8. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.6.16. Rest of MEA
      • 13.6.16.1. Overview
      • 13.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.16.3. Rest of MEA Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.6.16.4. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.6.16.5. Rest of MEA Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.6.16.6. Rest of MEA Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.6.16.7. Rest of MEA Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.6.16.8. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)

14. Key Vendor Analysis- Drug Repurposing Industry

  • 14.1. Competitive Benchmarking
    • 14.1.1. Competitive Dashboard
    • 14.1.2. Competitive Positioning
  • 14.2. Company Profiles
    • 14.2.1. Eli Lilly and Company
    • 14.2.2. GSK plc
    • 14.2.3. Amgen Inc.
    • 14.2.4. Biogen Inc.
    • 14.2.5. Pfizer Inc.
    • 14.2.6. Roche Holding AG
    • 14.2.7. Novartis AG
    • 14.2.8. AbbVie
    • 14.2.9. Amgen
    • 14.2.10. Boehringer Ingelheim
    • 14.2.11. Cyclica
    • 14.2.12. GlaxoSmithKline
    • 14.2.13. Vertex Pharmaceuticals
    • 14.2.14. Melior Discovery
    • 14.2.15. Pharnext
    • 14.2.16. Recursion Pharmaceuticals
    • 14.2.17. Revolution Medicines
    • 14.2.18. Sanofi
    • 14.2.19. Schwarz Pharma
    • 14.2.20. Valence Discovery
    • 14.2.21. Bayer AG
    • 14.2.22. Teva Pharmaceutical
    • 14.2.23. Others

15. 360 Degree Analyst View

16. Appendix

  • 16.1. Research Methodology
  • 16.2. References
  • 16.3. Abbreviations
  • 16.4. Disclaimer
  • 16.5. Contact Us